Literature DB >> 7542213

The selectins: vascular adhesion molecules.

T F Tedder1, D A Steeber, A Chen, P Engel.   

Abstract

The selectin family of adhesion molecules mediates the initial attachment of leukocytes to venular endothelial cells before their firm adhesion and diapedesis at sites of tissue injury and inflammation. The selectin family consists of three closely related cell-surface molecules with differential expression by leukocytes (L-selectin), platelets (P-selectin), and vascular endothelium (E- and P-selectin). The selectins have characteristic extracellular regions composed of an amino-terminal lectin domain that binds a carbohydrate ligand, an epidermal growth factor-like domain, and two to nine short repeat units homologous to domains found in complement binding proteins. In contrast to most other adhesion molecules, selectin function is restricted to leukocyte interactions with vascular endothelium. Multiple studies indicate that the selectins mediate neutrophil, monocyte, and lymphocyte rolling along the venular wall. The generation of selectin-deficient mice has confirmed these findings and provided further insight into how the overlapping functions of these receptors regulate inflammatory processes. Selectin-directed therapeutic agents are now proven to be effective in blocking many of the pathological effects resulting from leukocyte entry into sites of inflammation. Future studies are focused on how the selectins interact with the increasing array of other adhesion molecules and inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542213

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  173 in total

1.  Endothelial ligands for L-selectin: from lymphocyte recirculation to allograft rejection.

Authors:  S D Rosen
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Correlating the kinetics of cytokine-induced E-selectin adhesion and expression on endothelial cells.

Authors:  J D Levin; H P Ting-Beall; R M Hochmuth
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

3.  Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium.

Authors:  Y J Kim; L Borsig; H L Han; N M Varki; A Varki
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  P-Selectin: Basic Aspects.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

5.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

6.  Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis.

Authors:  Y Shimada; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

7.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 8.  Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation.

Authors:  D A Steeber; T F Tedder
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 9.  Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.

Authors:  J Panés; M Perry; D N Granger
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

10.  Platelet activation In mice and human Helicobacter pylori infection.

Authors:  J I Elizalde; J Gómez; J Panés; M Lozano; M Casadevall; J Ramírez; P Pizcueta; F Marco; F D Rojas; D N Granger; J M Piqué
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.